is a neuropeptide developed by the Institute of Molecular Genetics;
Russian Academy of Sciences, Moscow, Russia and “Lomonosov”
University, Moscow . Research started in 1982 and involved over
30 scientists in the fields of Neurochemistry, Neurobiology,
Neurology and Biochemistry from the Russian Federation.
focus was on a short fragment of ACTH, Pro8-Gly9-Pro10 ACTH(4-10)
and by dissociation of the combination of amino acids, substitution
and special linkages a peptide was synthesized which had unique
Extensive testing over a period of 14 years resulted in the approval
of the Russian Federation Ministry of Public Health and Pharmaceutical
Industry on 28 March, 1996, for the clinical use of SEMAX®
in the Russian Federation as a neuroactive peptide with endogenous
regulatory properties affecting cerebral cellular processes which
are beneficial in protecting and enhancing the recovery of cerebral
functions after ischemic insults like : brain stroke, closed head
injuries. Neurodegenerative processes like in Alzheimer’s
disease, Parkinson’s disease and Huntington’s Chorea.
also influences the intellectual capacities and memory as well
as concentration of normal, healthy persons subjected to stressful
working conditions, increasing their mental capacities and diminishing
the index of workload.